Abstract: The present invention relates to the field of pharmaceutical composition comprising “LIT-TB” derivatives. More particularly it relates to “LIT-TB” derivatives for use in the treatment of neurodegenerative diseases, and more particularly in the treatment of Huntington's disease. The invention also relates to the “LIT-TB” derivatives and preparation thereof.

Abstract: Embodiments of the present disclosure relate to methods of screening and optionally designing compounds as inhibitors of Mfd (Mutation Frequency Decline), such compounds being useful for the treatment of bacterial infections. Embodiments of the methods include culturing pathogenic bacteria expressing functional Mfd with various concentrations of 1 mM or less, incubating the cultures with and without nitric oxide stress conditions, evaluating bacterial survival in each of the cultures, and calculating the concentration of the molecule required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the untreated cultures and cultures following nitric oxide stress.

Abstract: Embodiments of the present disclosure relate to methods of screening and optionally designing compounds as inhibitors of Mfd (Mutation Frequency Decline), such compounds being useful for the treatment of bacterial infections. Embodiments of the methods include culturing pathogenic bacteria expressing functional Mfd with various concentrations of 1 mM or less, incubating the cultures with and without nitric oxide stress conditions, evaluating bacterial survival in each of the cultures, and calculating the concentration of the molecule required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the untreated cultures and cultures following nitric oxide stress.

Abstract: The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.

Abstract: The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.

Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.

Abstract: The new naphthamide derivatives according to the invention are characterized in that they correspond to the general formula (I), ##STR1## where X: represents either a hydrogen atom, or a chlorine or bromine atom, or an amino or aminoalkyl group, an aminosulphamoyl group, a sulphur-containing group such as thiocyanate, alkylthio, alkylsulphinyl or alkylsulphonyl, or a methoxy group, or a nitro group, or a cyano group, or an electron-attracting group;Y: represents an alkyl or alkenyl residue;Z: represents the residues originating from 2-aminomethyl-N-alkylpyrrolidine, 2-aminoethyl-N,N-diethylamine, 2-(aminoethyl)morpholine, 2-aminoethyl-N,N-dibutylamine, 4-amino-N-butylpiperidine or 2-(aminoethyl)pyrrolidine;R: a hydrogen or an OCH.sub.3 substituent.These new derivatives may be employed in the preparation of medicinal products intended for use as an antipsychotic, psychostimulatory, anti-autistic or antidepressant agent, an agent for treating Parkinson's disease or an antihypertensive agent.